Inhibikase Therapeutics IKT
NASDAQ IKT
$1.66 -0.05 (-2.92%)
At close: Oct 21, 2026 · 4:00 PM EDT

Inhibikase Therapeutics (IKT) EBIT Margin (2020 - 2026)

Updated

Inhibikase Therapeutics (IKT) recorded EBIT Margin of -440356600.00% in Q4 2023, down 440349780.36 percentage points from -6819.64% a year earlier and down 440350606.62 percentage points from the prior quarter.

Analysis

Inhibikase Therapeutics (IKT) EBIT Margin (2020 - 2026) Analysis & Trends

For FY2023, Inhibikase Therapeutics reported EBIT Margin of -7711.98%, up 6974.19 percentage points from FY2022.

  • Annual EBIT Margin has a three-year change of -7308.46 percentage points (FY2020 to FY2023).
  • Across earlier years, EBIT Margin came in at -14686.17% in FY2022 (-14209.94 pp), -476.23% in FY2021 (-72.71 pp) and -403.52% in FY2020.
  • The Q4 2023 figure is the lowest quarterly EBIT Margin in data going back to Q1 2020.
  • On a year-over-year basis, EBIT Margin rose in four of the last eight quarters, with an average year-over-year change of -55014269.26 percentage points.
  • Peak year-over-year performance for EBIT Margin in the last five years was a gain of 252514.77 percentage points in Q4 2022, against a drop of 440349780.36 percentage points in Q4 2023 at the low end.
  • Per Business Quant, the preceding three quarters came in at -5993.38% (Q3 2023), -5328.07% (Q2 2023) and -7307.62% (Q1 2023).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 28.21%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 37.86%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -3.52%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 32.97%
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 20.57%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 34.95%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -133.21%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 28.37%
10 Inhibikase Therapeutics 288.92 Mn -296.56 Mn - -1,442.08%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -1,442.08%
Mar 31, 2026 -1,221.15%
Dec 31, 2025 -1,324.49%
Sep 30, 2025 -1,521.86%
Jun 30, 2025 -1,181.59%
Mar 31, 2025 -1,588.00%
Dec 31, 2023 -440,356,600.00%
Sep 30, 2023 -5,993.38%
Jun 30, 2023 -5,328.07%
Mar 31, 2023 -7,307.62%
Dec 31, 2022 -6,819.64%
Sep 30, 2022 -61,899.59%
Jun 30, 2022 -70,817.14%
Mar 31, 2022 -10,081.46%
Dec 31, 2021 -259,334.41%
Sep 30, 2021 -1,361.22%
Jun 30, 2021 -192.83%
Mar 31, 2021 -186.56%
Dec 31, 2020 -704.66%
Sep 30, 2020 -1,761.44%
API Access

Inhibikase Therapeutics EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=IKT&period=max&api_key=YOUR_API_KEY